{"id":11464,"date":"2024-12-17T09:30:00","date_gmt":"2024-12-17T08:30:00","guid":{"rendered":"https:\/\/www.pegasoftsrl.it\/?p=11464"},"modified":"2024-12-11T12:34:05","modified_gmt":"2024-12-11T11:34:05","slug":"gene-editing-the-first-crispr-therapy-to-reach-patients","status":"publish","type":"post","link":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/","title":{"rendered":"Gene editing, the first Crispr therapy to reach patients"},"content":{"rendered":"\n<h2 class=\"wp-block-heading\">Crispr therapy heralds a new era in genetic medicine, with indications for sickle cell anaemia and beta thalassemia.<\/h2>\n\n\n\n<!--more-->\n\n\n\n<p class=\"wp-block-paragraph\">CRISPR technology, or <strong>Clustered Regularly Interspaced Short Palindromic Repeats<\/strong>, makes it possible to modify the nucleic acids that make up the genome of all living organisms. A discovery that has earned Emmanuelle Charpentier and Jennifer Doudna the 2020 Nobel Prize in Chemistry for their ability to &#8220;rewrite the code of life&#8221;. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">But &#8220;gene editing&#8221;, <strong>which acts as a DNA &#8220;proofreader&#8221;, could be the real gene therapy of the future.<\/strong><\/p>\n\n\n<div class=\"wp-block-table-of-contents-block-table-of-contents-block\"><div class=\"eb-parent-wrapper eb-parent-eb-toc-byby7 \"><div class=\"eb-toc-container eb-toc-byby7  eb-toc-is-not-sticky eb-toc-not-collapsible eb-toc-initially-not-collapsed eb-toc-scrollToTop style-1 list-style-none\" data-scroll-top=\"false\" data-scroll-top-icon=\"fas fa-angle-up\" data-collapsible=\"false\" data-sticky-hide-mobile=\"false\" data-sticky=\"false\" data-scroll-target=\"scroll_to_toc\" data-copy-link=\"false\" data-editor-type=\"\" data-hide-desktop=\"false\" data-hide-tab=\"false\" data-hide-mobile=\"true\" data-itemcollapsed=\"false\"><div class=\"eb-toc-header\"><div class=\"eb-toc-title\">What you will find in this article:<\/div><\/div><div class=\"eb-toc-wrapper \" data-headers=\"[{&quot;level&quot;:3,&quot;content&quot;:&quot;Crispr technique&quot;,&quot;text&quot;:&quot;Crispr technique&quot;,&quot;link&quot;:&quot;crispr-technique&quot;},{&quot;level&quot;:3,&quot;content&quot;:&quot;First Crispr therapy doses&quot;,&quot;text&quot;:&quot;First Crispr therapy doses&quot;,&quot;link&quot;:&quot;first-crispr-therapy-doses&quot;},{&quot;level&quot;:3,&quot;content&quot;:&quot;How does Casgevy work?&quot;,&quot;text&quot;:&quot;How does Casgevy work?&quot;,&quot;link&quot;:&quot;how-does-casgevy-work&quot;},{&quot;level&quot;:3,&quot;content&quot;:&quot;Prospects and obstacles&quot;,&quot;text&quot;:&quot;Prospects and obstacles&quot;,&quot;link&quot;:&quot;prospects-and-obstacles&quot;}]\" data-visible=\"[false,false,true,false,false,false]\" data-delete-headers=\"[{&quot;label&quot;:&quot;Crispr technique&quot;,&quot;value&quot;:&quot;crispr-technique&quot;,&quot;isDelete&quot;:false},{&quot;label&quot;:&quot;First Crispr therapy doses&quot;,&quot;value&quot;:&quot;first-crispr-therapy-doses&quot;,&quot;isDelete&quot;:false},{&quot;label&quot;:&quot;How does Casgevy work?&quot;,&quot;value&quot;:&quot;how-does-casgevy-work&quot;,&quot;isDelete&quot;:false},{&quot;label&quot;:&quot;Prospects and obstacles&quot;,&quot;value&quot;:&quot;prospects-and-obstacles&quot;,&quot;isDelete&quot;:false}]\" data-smooth=\"true\" data-top-offset=\"\"><div class=\"eb-toc__list-wrap\"><ul class=\"eb-toc__list\"><li><a href=\"#crispr-technique\">Crispr technique<\/a><li><a href=\"#first-crispr-therapy-doses\">First Crispr therapy doses<\/a><li><a href=\"#how-does-casgevy-work\">How does Casgevy work?<\/a><li><a href=\"#prospects-and-obstacles\">Prospects and obstacles<\/a><\/ul><\/div><\/div><\/div><\/div><\/div>\n\n\n<h3 class=\"wp-block-heading\">Crispr technique<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The real revolution in this field came in 2012 with <strong>the discovery of the Crispr-Cas9 system<\/strong>. In the study published in Science, Charpentier (director of the Max Planck Unit for the Science of Pathogens in Berlin) and Doudna (professor at the University of California) showed how the Cas9 protein can be used as a kind of molecular scissors capable of cutting a target DNA, with the possibility of programming it to make specific changes to the genome of a cell, be it animal, human or plant. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">As a result of the cut made by Cas9,<strong> it is possible to remove harmful DNA sequences from the target genome or to replace sequences<\/strong>, e.g. by correcting disease-causing mutations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>The Cas9 target is programmed by an RNA molecule called guide RNA<\/strong>, which is easily modified in the laboratory. Once attached to Cas9, the guide RNA acts as a kind of leash, anchoring Cas9 to the chosen target DNA sequence. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The system was originally identified by studying bacteria, where the Cas9 protein acts as a molecular scissors to help these microorganisms protect themselves from pathogenic viruses. Between 2012 and 2013, two American research groups from UC Berkeley and MIT Boston first demonstrated that this technology could be used as <strong>a biotechnological tool to cut specific DNA sequences within the genome of a non-bacterial cell.<\/strong> <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">This discovery was <strong>a real revolution for biomedical research<\/strong>, because for the first time it was possible to introduce the desired changes in the genome in a simple, effective, fast and inexpensive way.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">First Crispr therapy doses<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">The <strong>Crispr genome editing<\/strong> therapy, called <strong>Casgevy<\/strong>, is aimed at people with <strong>sickle cell anaemia<\/strong> and a related blood disorder, <strong>beta thalassemia<\/strong> (also known as Mediterranean anaemia). It was developed <strong>by Crispr Therapeutics, a Swiss company co-founded by Nobel laureate Emmanuelle Charpentier, and Vertex Pharmaceuticals, a Boston-based biotech company.<\/strong> <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The treatment was approved by regulators in the UK in November 2023, followed by the US and the EU in December. <\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large\"><img data-recalc-dims=\"1\" fetchpriority=\"high\" decoding=\"async\" width=\"1024\" height=\"690\" src=\"https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/CRISPR_heroes_Shutterstock_HFARM_202105_image-3-2.jpg?resize=1024%2C690&#038;ssl=1\" alt=\"Crispr technology @Shutterstock\" class=\"wp-image-11407\" srcset=\"https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/CRISPR_heroes_Shutterstock_HFARM_202105_image-3-2.jpg?resize=1024%2C690&amp;ssl=1 1024w, https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/CRISPR_heroes_Shutterstock_HFARM_202105_image-3-2.jpg?resize=300%2C202&amp;ssl=1 300w, https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/CRISPR_heroes_Shutterstock_HFARM_202105_image-3-2.jpg?resize=768%2C517&amp;ssl=1 768w, https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/CRISPR_heroes_Shutterstock_HFARM_202105_image-3-2.jpg?resize=720%2C485&amp;ssl=1 720w, https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/CRISPR_heroes_Shutterstock_HFARM_202105_image-3-2.jpg?w=1336&amp;ssl=1 1336w\" sizes=\"(max-width: 1000px) 100vw, 1000px\" \/><figcaption class=\"wp-element-caption\">@Shutterstock<\/figcaption><\/figure>\n<\/div>\n\n\n<p class=\"wp-block-paragraph\">During a meeting with investors, <strong>Vertex <\/strong><strong>Pharmaceuticals<\/strong>, the pharmaceutical company marketing Casgevy, announced that in the third quarter of this year <strong>the therapy was administered to a person for the first time outside of a clinical trial<\/strong>, from which it made <strong>USD 2 million<\/strong> (Casgevy debuted with a price tag of USD 2.2 million in the US).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;<em>Cagevy has been enthusiastically received by patients, physicians and policymakers, and the launch is progressing well in all regions,<\/em>&#8221; Vertex Chief Operating Officer Stuart Arbuckle said at the meeting, adding that <strong>more patients are accessing the treatment<\/strong> commercially. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">How does Casgevy work?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">People with<strong> sickle cell anaemia or beta thalassaemia<\/strong> do not produce healthy haemoglobin, the substance in red blood cells that carries oxygen throughout the body, due to errors in the haemoglobin gene. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">People with sickle cell anaemia have harder, crescent-shaped red blood cells that, when they clump together, block blood flow, causing severe pain that can last for hours or days and land people in hospital. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In beta thalassaemia, the body does not produce enough haemoglobin, leading to anaemia. People with severe forms of the disease need regular blood transfusions for life. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Casgevy uses Crispr <strong>to modify a person&#8217;s cells to produce healthy haemoglobin<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The treatment involves <strong>collecting the patient&#8217;s blood-forming stem cells<\/strong>, which are then sent to a laboratory to be modified. Before receiving the infusion of new cells, patients must undergo <strong>chemotherapy <\/strong>to prepare their bone marrow to receive the cells. Once administered, the cells reach the bone marrow where they begin to produce new red blood cells with healthy haemoglobin.  <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Prospects and obstacles<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">In clinical trials, Casgevy <strong>significantly reduced or eliminated debilitating pain crises<\/strong> in people with sickle cell anaemia and allowed most beta-thalassemia patients <strong>to stop blood transfusions<\/strong>. For some of these people, it is a functional cure. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Vertex estimates that <strong>around 35,000 patients with the two diseases in the US and Europe<\/strong> could benefit from Casgevy. The company is investing in expanding production of the therapy and in September received approval for a third manufacturing facility, Arbuckle said. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In some cases, the need to undergo <strong>chemotherapy<\/strong>, which can cause <strong>infertility<\/strong>, remains <strong>a major obstacle <\/strong>for those seeking access to Casgevy. Another complication is <strong>the long and arduous process of harvesting the cells<\/strong> and the need to stay in hospital for weeks after the infusion. In short, the first Crispr-based drug is here, but it remains to be seen how well it will be received by patients.  <\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Sources and Data<\/h4>\n\n\n\n<ul class=\"wp-block-list\">\n<li><a href=\"https:\/\/www.wired.it\/article\/crispr-casgevy-somministrazione-primi-pazienti\/\">Crispr, la prima terapia sta arrivando ai pazienti | Wired Italia<\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/am.pictet.com\/pictetperte\/tecnologia-e-innovazione\/2021\/tecnologia-crispr-a-che-punto-e-l-editing-genetico-oggi\">Tecnologia CRISPR: a che punto \u00e8 l\u2019editing genetico oggi? <\/a><\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Crispr therapy heralds a new era in genetic medicine, with indications for sickle cell anaemia and beta thalassemia.<\/p>\n","protected":false},"author":2,"featured_media":11410,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_eb_attr":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":false,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[378,393],"tags":[701,473,699,700],"class_list":["post-11464","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-biology-and-medicine","category-technology","tag-crispr-therapy","tag-genomics","tag-innovation","tag-technologies"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Gene editing, the first Crispr therapy to reach patients - Pegasoft srl<\/title>\n<meta name=\"description\" content=\"Crispr therapy heralds a new era in genetic medicine, with indications for sickle cell anaemia and beta thalassemia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Gene editing, the first Crispr therapy to reach patients - Pegasoft srl\" \/>\n<meta property=\"og:description\" content=\"Crispr therapy heralds a new era in genetic medicine, with indications for sickle cell anaemia and beta thalassemia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"Pegasoft srl\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pegasoftsrlcs\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-17T08:30:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/header-blog-terapia-crispr-pazienti.jpg?fit=870%2C435&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"870\" \/>\n\t<meta property=\"og:image:height\" content=\"435\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Elisabetta\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@pegasoft_\" \/>\n<meta name=\"twitter:site\" content=\"@pegasoft_\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Elisabetta\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/\"},\"author\":{\"name\":\"Elisabetta\",\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/#\\\/schema\\\/person\\\/50ef23a3e701620adcc0fd7f0f514a01\"},\"headline\":\"Gene editing, the first Crispr therapy to reach patients\",\"datePublished\":\"2024-12-17T08:30:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/\"},\"wordCount\":853,\"publisher\":{\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.pegasoftsrl.it\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/header-blog-terapia-crispr-pazienti.jpg?fit=870%2C435&ssl=1\",\"keywords\":[\"CRISPR therapy\",\"Genomics\",\"Innovation\",\"Technologies\"],\"articleSection\":[\"Biology and medicine\",\"Technology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/\",\"url\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/\",\"name\":\"Gene editing, the first Crispr therapy to reach patients - Pegasoft srl\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.pegasoftsrl.it\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/header-blog-terapia-crispr-pazienti.jpg?fit=870%2C435&ssl=1\",\"datePublished\":\"2024-12-17T08:30:00+00:00\",\"description\":\"Crispr therapy heralds a new era in genetic medicine, with indications for sickle cell anaemia and beta thalassemia.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/www.pegasoftsrl.it\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/header-blog-terapia-crispr-pazienti.jpg?fit=870%2C435&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.pegasoftsrl.it\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/header-blog-terapia-crispr-pazienti.jpg?fit=870%2C435&ssl=1\",\"width\":870,\"height\":435,\"caption\":\"La tecnologia Crispr @Shutterstock\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/gene-editing-the-first-crispr-therapy-to-reach-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Gene editing, the first Crispr therapy to reach patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/\",\"name\":\"Pegasoft srl\",\"description\":\"Wings of Technology\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/#organization\"},\"alternateName\":\"Pegasoft\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/#organization\",\"name\":\"Pegasoft srl\",\"alternateName\":\"Pegasoft\",\"url\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/www.pegasoftsrl.it\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Pegasoft-logo-696x696-1.png?fit=696%2C696&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/www.pegasoftsrl.it\\\/wp-content\\\/uploads\\\/2023\\\/09\\\/Pegasoft-logo-696x696-1.png?fit=696%2C696&ssl=1\",\"width\":696,\"height\":696,\"caption\":\"Pegasoft srl\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pegasoftsrlcs\",\"https:\\\/\\\/x.com\\\/pegasoft_\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/pegasoft\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pegasoftsrl.it\\\/en\\\/#\\\/schema\\\/person\\\/50ef23a3e701620adcc0fd7f0f514a01\",\"name\":\"Elisabetta\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/28fe46c889ca711be6e5d902f14e3f3583be020d7ed3217c2da2e07fead38bda?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/28fe46c889ca711be6e5d902f14e3f3583be020d7ed3217c2da2e07fead38bda?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/28fe46c889ca711be6e5d902f14e3f3583be020d7ed3217c2da2e07fead38bda?s=96&d=mm&r=g\",\"caption\":\"Elisabetta\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Gene editing, the first Crispr therapy to reach patients - Pegasoft srl","description":"Crispr therapy heralds a new era in genetic medicine, with indications for sickle cell anaemia and beta thalassemia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/","og_locale":"en_US","og_type":"article","og_title":"Gene editing, the first Crispr therapy to reach patients - Pegasoft srl","og_description":"Crispr therapy heralds a new era in genetic medicine, with indications for sickle cell anaemia and beta thalassemia.","og_url":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/","og_site_name":"Pegasoft srl","article_publisher":"https:\/\/www.facebook.com\/pegasoftsrlcs","article_published_time":"2024-12-17T08:30:00+00:00","og_image":[{"width":870,"height":435,"url":"https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/header-blog-terapia-crispr-pazienti.jpg?fit=870%2C435&ssl=1","type":"image\/jpeg"}],"author":"Elisabetta","twitter_card":"summary_large_image","twitter_creator":"@pegasoft_","twitter_site":"@pegasoft_","twitter_misc":{"Written by":"Elisabetta","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/#article","isPartOf":{"@id":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/"},"author":{"name":"Elisabetta","@id":"https:\/\/www.pegasoftsrl.it\/en\/#\/schema\/person\/50ef23a3e701620adcc0fd7f0f514a01"},"headline":"Gene editing, the first Crispr therapy to reach patients","datePublished":"2024-12-17T08:30:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/"},"wordCount":853,"publisher":{"@id":"https:\/\/www.pegasoftsrl.it\/en\/#organization"},"image":{"@id":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/header-blog-terapia-crispr-pazienti.jpg?fit=870%2C435&ssl=1","keywords":["CRISPR therapy","Genomics","Innovation","Technologies"],"articleSection":["Biology and medicine","Technology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/","url":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/","name":"Gene editing, the first Crispr therapy to reach patients - Pegasoft srl","isPartOf":{"@id":"https:\/\/www.pegasoftsrl.it\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/header-blog-terapia-crispr-pazienti.jpg?fit=870%2C435&ssl=1","datePublished":"2024-12-17T08:30:00+00:00","description":"Crispr therapy heralds a new era in genetic medicine, with indications for sickle cell anaemia and beta thalassemia.","breadcrumb":{"@id":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/#primaryimage","url":"https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/header-blog-terapia-crispr-pazienti.jpg?fit=870%2C435&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/header-blog-terapia-crispr-pazienti.jpg?fit=870%2C435&ssl=1","width":870,"height":435,"caption":"La tecnologia Crispr @Shutterstock"},{"@type":"BreadcrumbList","@id":"https:\/\/www.pegasoftsrl.it\/en\/gene-editing-the-first-crispr-therapy-to-reach-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pegasoftsrl.it\/en\/"},{"@type":"ListItem","position":2,"name":"Gene editing, the first Crispr therapy to reach patients"}]},{"@type":"WebSite","@id":"https:\/\/www.pegasoftsrl.it\/en\/#website","url":"https:\/\/www.pegasoftsrl.it\/en\/","name":"Pegasoft srl","description":"Wings of Technology","publisher":{"@id":"https:\/\/www.pegasoftsrl.it\/en\/#organization"},"alternateName":"Pegasoft","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pegasoftsrl.it\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.pegasoftsrl.it\/en\/#organization","name":"Pegasoft srl","alternateName":"Pegasoft","url":"https:\/\/www.pegasoftsrl.it\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.pegasoftsrl.it\/en\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2023\/09\/Pegasoft-logo-696x696-1.png?fit=696%2C696&ssl=1","contentUrl":"https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2023\/09\/Pegasoft-logo-696x696-1.png?fit=696%2C696&ssl=1","width":696,"height":696,"caption":"Pegasoft srl"},"image":{"@id":"https:\/\/www.pegasoftsrl.it\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pegasoftsrlcs","https:\/\/x.com\/pegasoft_","https:\/\/www.linkedin.com\/company\/pegasoft\/"]},{"@type":"Person","@id":"https:\/\/www.pegasoftsrl.it\/en\/#\/schema\/person\/50ef23a3e701620adcc0fd7f0f514a01","name":"Elisabetta","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/28fe46c889ca711be6e5d902f14e3f3583be020d7ed3217c2da2e07fead38bda?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/28fe46c889ca711be6e5d902f14e3f3583be020d7ed3217c2da2e07fead38bda?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/28fe46c889ca711be6e5d902f14e3f3583be020d7ed3217c2da2e07fead38bda?s=96&d=mm&r=g","caption":"Elisabetta"}}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/i0.wp.com\/www.pegasoftsrl.it\/wp-content\/uploads\/2024\/11\/header-blog-terapia-crispr-pazienti.jpg?fit=870%2C435&ssl=1","_links":{"self":[{"href":"https:\/\/www.pegasoftsrl.it\/en\/wp-json\/wp\/v2\/posts\/11464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pegasoftsrl.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pegasoftsrl.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pegasoftsrl.it\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pegasoftsrl.it\/en\/wp-json\/wp\/v2\/comments?post=11464"}],"version-history":[{"count":3,"href":"https:\/\/www.pegasoftsrl.it\/en\/wp-json\/wp\/v2\/posts\/11464\/revisions"}],"predecessor-version":[{"id":11467,"href":"https:\/\/www.pegasoftsrl.it\/en\/wp-json\/wp\/v2\/posts\/11464\/revisions\/11467"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pegasoftsrl.it\/en\/wp-json\/wp\/v2\/media\/11410"}],"wp:attachment":[{"href":"https:\/\/www.pegasoftsrl.it\/en\/wp-json\/wp\/v2\/media?parent=11464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pegasoftsrl.it\/en\/wp-json\/wp\/v2\/categories?post=11464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pegasoftsrl.it\/en\/wp-json\/wp\/v2\/tags?post=11464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}